Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Histamine H3 receptor ligands claimed by Merck & Co.

July 13, 2010

EMA commences review of rosiglitazone-containing medicines

July 12, 2010

Ardea describes next-generation URAT-1 inhibitor RDEA-684

July 12, 2010

Clinical trials show potential of ASP-1941 to treat type 2 diabetes

July 12, 2010

Sanwa describes preclinical pharmacology of SKL-18287 and SKL-19014

July 12, 2010

Oramed and sanofi-aventis enter agreement for oral insulin capsules

July 9, 2010

Evatanepag accelerates fracture healing in phase II trial

July 9, 2010

TRUST trial further explores efficacy and safety of corifollitropin alfa

July 9, 2010

FDA grants orphan drug status to SBC-102 for lysosomal acid lipase deficiency

July 8, 2010

NOXXON to begin phase Ib trial of NOX-E36 for diabetes

July 8, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...